Boehringer Ingelheim Pharmaceuticals has broken ground on a $65 million R&D center at its site located in the Ridgefield-Danbury area in western Connecticut. Construction of the new building, which replaces an existing one, is expected to be completed in 2014

The center will not add many permanent jobs, according to James Baxter, Boehringer's U.S. senior vice president for development. However, he noted the company's 25 employees R&D facility will remain in Ridgefield, as will other positions (about 100) dependent upon the work performed at the facility.

Based in Ridgefield, CT, Boehringer Ingelheim Pharmaceuticals is the largest U.S. subsidiary of Boehringer Ingelheim Corporation. It also is a member of the Boehringer Ingelheim group of companies (headquartered in Ingelheim, Germany), which operates globally with 145 affiliates and more than 42,000 employees.